AboutContactsEditorial StaffEditorial CouncilArchiveFor AuthorsFor Reviewers

Cytisine Use for Tobacco Addiction Treatment: Comments on the Russian Guidelines for Prevention of Chronic Non-Communicable Diseases

Journal «MEDICINA» ¹ 3, 2022, pp.13-28 (Research)

Authors

Bel'diev S. N.
MD, PhD, Associate Professor, Chair of therapy and cardiology1

Trufanova G. Yu.
MD, PhD, Associate Professor, Chair of therapy and cardiology1

Medvedeva I. V.
MD, PhD, Associate Professor, Chair of therapy and cardiology1

Egorova I. V.
MD, PhD, Associate Professor, Chair of therapy and cardiology1

Berezina E. I.
MD, PhD, Associate Professor, Chair of therapy and cardiology1

Platonov D. Yu.
MD, PhD, MPH, Head, Chair of therapy and cardiology1

1 - Tver State Medical University, Tver, Russia

Corresponding Author

Bel'diev Sergey; e-mail: sbeldiev@yandex.ru.

Conflict of interest

Authors have no conflict of interest.

Funding

The study had no sponsorship.

Abstract

The National guidelines «2022 Prevention of chronic non-communicable diseases in the Russian Federation» in the subsection «Pharmacotherapy of tobacco dependence» contain insufficiently correct statements about contraindications for use, efficacy and tolerability of cytisine. This paper presents a detailed analysis of these statements.

Key words

tobacco dependence treatment, cytisine, nicotine replacement therapy, varenicline

DOI

References

1. Drapkina O.M., Kontsevaya A.V., Kalinina A.M., Avdeev S.M., Agaltsov M.V., Alexandrova L.M., et al. Profilaktika hronicheskih neinfekcionnyh zabolevanij v Rossijskoj Federacii. Nacional'noe rukovodstvo 2022 [2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines]. Kardiovaskuljarnaja terapija i profilaktika [Cardiovascular Therapy and Prevention] 2022; 21(4): 5-232, doi: 10.15829/1728-8800-2022-3235. (In Russ.)

2. Gambaryan M.G., Drapkina O.M. Zashhita zdorov'ja zhenshhin ot vozdejstvija tabachnogo dyma, profilaktika i lechenie potreblenija tabaka i tabachnoj zavisimosti u zhenshhin [Protecting women's health from exposure to tobacco smoke, preventing and treating tobacco use and tobacco dependence in women]. Voronezh: Kanctovary; 2019. Available at: https://gnicpm.ru/wp-content/uploads/2020/07/zashhita-zdorovya-zhenshhin-ot-vozdejstviya-tabachnogo-dyma-profilaktika-i-lechenie-potrebleniya-tabaka-i-tabachnoj-zavisimosti-u-zhenshhin.pdf. Accessed: 07.13.2022. (In Russ.)

3. Drapkina O.M., Gambaryan M.G., Kalinina A.M., Shepel R.N. Organizacija i okazanie medicinskoj pomoshhi, napravlennoj na prekrashhenie potreblenija tabaka, lechenie tabachnoj zavisimosti i posledstvij potreblenija tabaka [Organization and provision of medical care aimed at cessation of tobacco consumption, treatment of tobacco dependence and the consequences of tobacco consumption]. Voronezh: Kanctovary; 2019. Available at: https://gnicpm.ru/wp-content/uploads/2020/07/organizacziya-i-okazanie-mediczinskoj-pomoshhi-napravlennoj-na-prekrashhenie-potrebleniya-tabaka.pdf. Accessed: 07.13.2022. (In Russ.)

4. Gambaryan M.G., Drapkina O.M. Algoritmy okazanija pomoshhi kurjashhim v sisteme zdravoohranenija. «Pozvol'te sprosit': Vy kurite?» [Algorithms for smoking-cessation support in health care. «Let me ask You: do You smoke?»]. Profilakticheskaja medicina [The Russian Journal of Preventive Medicine] 2019; 22(3): 57‑72, doi: 10.17116/profmed20192203157. (In Russ.).

5. Instrukcija po medicinskomu primeneniju preparata Tabeks (mezhdunarodnoe nepatentovannoe naimenovanie: citizin). Data gosudarstvennoj registracii: 05.02.2010 [Tabex (international non-proprietary name: cytisine): summary of product characteristics. Date of state registration: February 5, 2010]. Available at: https://grls.rosminzdrav.ru/Grls­_View­_v2.aspx?routingGuid=906af015-1acf-44ba-ac8f-c65664a21433&t=. Accessed: 07.13.2022. (In Russ.)

6. Asmoken (international name: cytisine): summary of product characteristics. Available at: https://myhealthbox.eu/en/asmoken/4425544. Accessed: 07.13.2022.

7. Citidaron (international name: cytisine): summary of product characteristics. Available at: https://myhealthbox.eu/en/citidaron-15-mg-tablets/4817416. Accessed: 07.13.2022.

8. Novynta (international name: cytisine): summary of product characteristics. Available at: https://myhealthbox.eu/en/novynta-15-mg-tablets/6377180. Accessed: 07.13.2022.

9. Desmoxan (international name: cytisine): package insert. Available at: https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/Desmoxan.pdf. Accessed: 07.13.2022.

10. Instrukcija po medicinskomu primeneniju lekarstvennogo preparata Resigar A (mezhdunarodnoe nepatentovannoe naimenovanie: citizin). Data gosudarstvennoj registracii: 09.10.2020 [Recigar A (international non-proprietary name: cytisine): summary of product characteristics. Date of state registration: October 9, 2020]. Available at: https://grls.rosminzdrav.ru/Grls­_View­_v2.aspx?routingGuid=75ac7965-0345-4df7-8ce8-4b33fa2d6585. Accessed: 07.13.2022. (In Russ.)

11. Instrukcija po medicinskomu primeneniju lekarstvennogo preparata Stopadiks (mezhdunarodnoe nepatentovannoe naimenovanie: citizin). Data gosudarstvennoj registracii: 23.08.2021 [Stopadix (international non-proprietary name: cytisine): summary of product characteristics. Date of state registration: August 23, 2021]. Available at: https://grls.rosminzdrav.ru/Grls­_View­_v2.aspx?routingGuid=8aacbd53-bbce-403f-a06d-6eb9a2108623. Accessed: 07.13.2022. (In Russ.)

12. Instrukcija po medicinskomu primeneniju lekarstvennogo preparata Tabenova (mezhdunarodnoe nepatentovannoe naimenovanie: citizin). Data gosudarstvennoj registracii: 25.04.2022 [Tabenova (international non-proprietary name: cytisine): summary of product characteristics. Date of state registration: April 25, 2022]. Available at: https://grls.rosminzdrav.ru/Grls­_View­_v2.aspx?routingGuid=fbb132b9-a14f-47b7-91fb-18a066c98d50. Accessed: 07.13.2022. (In Russ.)

13. Bel'diev S.N., Andreeva E.V., Berezina E.I., Egorova I.V., Medvedeva I.V., Platonov D.Yu. Pochemu nikorandil ne rassmatrivaetsja kak antianginal'nyj preparat pervoj linii [Why nicorandil is not considered to be the first-line antianginal drug]. Medicina [Medicine] 2020; 8(3): 25-47, doi: 10.29234/2308-9113-2020-8-3-25-47. (In Russ.)

14. Bel'diev S.N., Egorova I.V., Kononova A.G., Medvedeva I.V., Platonov D.Yu., Kolbasnikov S.V. Mify o lekarstvennyh vzaimodejstvijah Dzhozamicina [Myths about drug interactions of Josamycin]. Medicina [Medicine] 2020; 8(2): 10-30, doi: 10.29234/2308-9113-2020-8-2-10-30. (In Russ.)

15. Petrova E.D., Platonova M.D., Bel'diev S.N., Egorova I.V, Platonon D.Yu. Opisanie ul'cerogennyh effektov nikorandila v evropejskoj i otechestvennoj instrukcijah po medicinskomu primeneniju preparata [Description of nicorandilinduced ulceration in European and Russian instructions for the medical use of the drug]. Molodezh' i medicinskaja nauka: stat'i VI Vserossijskoj mezhvuzovskoj nauchno-prakticheskoj konferencii molodyh uchenyh s mezhdunarodnym uchastiem (Tver', 22 sentjabrja 2018 g.) [Youth and medical science: articles of VI Russian interuniversity scientific and practical conference of young scientists with international participation (Tver, September 22, 2018)]. Tver', 2019. P. 314-317. (In Russ.)

16. Bel'diev S.N. Vzaimodejstvie rivaroksabana s amiodaronom, verapamilom i diltiazemom u pacientov s fibrilljaciej predserdij: terra incognita [Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita]. Racional'naja farmakoterapija v kardiologii [Rational Pharmacotherapy in Cardiology] 2016; 12(1): 101-105, doi: 10.20996/1819-6446-2016-12-1-101-105. (In Russ.)

17. Bel'diev S.N. Prakticheskie aspekty primenenija apiksabana v klinicheskoj praktike: prodolzhenie temy [Practical aspects of apixaban use in clinical practice: continuing the theme]. Racional'naja farmakoterapija v kardiologii [Rational Pharmacotherapy in Cardiology] 2015; 11(5): 543-547, doi: 10.20996/1819-6446-2015-11-5-543-547. (In Russ.)

18. Hajek P., McRobbie H., Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax 2013; 68(11): 1037-1042, doi: 10.1136/thoraxjnl-2012-203035

19. Vinnikov D., Brimkulov N., Burjubaeva A. A double-blind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers. Journal of Smoking Cessation 2008; 3(1): 57-62, doi: 10.1375/jsc.3.1.57

20. West R., Zatonski W., Cedzynska M., Lewandowska D., Pazik J., Aveyard P., et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011; 365(13): 1193-1200, doi: 10.1056/NEJMoa1102035

21. Paun D., Franze J. Raucherentwöhnung mit cytisinhaltigen «Tabex»-Tabletten [Breaking the smoking habit using cytisin containing «Tabex» tablets]. Das Deutsche Gesundheitswesen [Dtsch Gesundheitsw] 1968; 23(44): 2088-2091. (In German).

22. Scharfenberg G., Benndorf S., Kempe G. Cytisin (Tabex) als medikamentöse Raucherentwöhnungshilfe [Cytisine (Tabex) as a pharmaceutical aid in stopping smoking]. Das Deutsche Gesundheitswesen [Dtsch Gesundheitsw] 1971; 26(10): 463-465. (In German)

23. Schmidt F. Medikamentöse Unterstützung der Raucherentwöhnung. Bericht über Versuche an über 5000 Rauchern im Doppelblindversuch [Medical support of nicotine withdrawal. Report on a double blind trail in over 5000 smokers]. MMW, Münchener medizinische Wochenschrift [MMW Munch Med Wochenschr] 1974; 116(11): 557-564. (In German)

24. Marakulin V.S., Komarov V.M., Chuprin V.V. Ob opyte lechenija nikotinizma [Treatment of nicotinism]. Voenno-medicinskij zhurnal [Journal of Military Medicine] 1984; 1: 55-58. (In Russ.)

25. Monova A., Monova D., Petrov V., Peneva E., Todorova M., Petrova M. Final report on double blind, placebo controlled, randomized clinical study for evaluation of efficacy, safety and tolerability of Tabex in patients with chronic nicotinism (tabacism): TAB‐SPH‐04014. Sopharma plc unpublished report 2004.

26. Stead L.F., Perera R., Bullen C., Mant D., Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; (1): CD000146, doi: 10.1002/14651858.CD000146.pub3

27. Hughes J.R., Stead L.F., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; (1): CD000031, doi: 10.1002/14651858.CD000031.pub3

28. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; (4): CD006103, doi: 10.1002/14651858.CD006103.pub6

29. Walker N., Howe C., Glover M., McRobbie H., Barnes J., Nosa V., et al. Cytisine versus nicotine for smoking cessation. N Engl J Med 2014; 371(25): 2353-2362, doi: 10.1056/NEJMoa1407764

30. Courtney R.J., McRobbie H., Tutka P., Weaver N.A., Petrie D., Mendelsohn C.P., et al. Effect of cytisine vs varenicline on smoking cessation: a randomized clinical trial. JAMA 2021; 326(1): 56-64, doi: 10.1001/jama.2021.7621

31. Walker N., Smith B., Barnes J., Verbiest M., Parag V., Pokhrel S., et al. Cytisine versus varenicline for smoking cessation in New Zealand indigenous Māori: a randomized controlled trial. Addiction 2021; 116(10): 2847-2858, doi: 10.1111/add.15489

32. Karnieg T., Wang X. Cytisine for smoking cessation. CMAJ 2018; 190(19): E596, doi: 10.1503/cmaj.171371

33. Gambaryan M.G. Hronicheskie respiratornye zabolevanija i potreblenie tabaka. Obzor [Chronic respiratory disease and tobacco consumption. Review]. Meditsinskiy sovet [Medical Council] 2016; (17): 144-152, doi: 10.21518/2079-701X-2016-17-144-152. (In Russ.)

34. Gambaryan M.G., Drapkina O.M. Hronicheskaja obstruktivnaja bolezn' legkih i kurenie tabaka: principy i puti profilaktiki (obzor) [Chronic obstructive pulmonary disease and smoking: prevention principles and ways: a review]. Profilakticheskaja medicina [The Russian Journal of Preventive Medicine] 2017; 20(5): 74‑82, doi: 10.17116/profmed201720574-82. (In Russ.)

35. Bader P., McDonald P., Selby P. An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts. Tob Control 2009; 18(1): 34-42, doi: 10.1136/tc.2008.025635

36. West R., Raw M., McNeill A., Stead L., Aveyard P., Bitton J., et al. Health-care interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national guideline development. Addiction 2015; 110(9): 1388-1403, doi: 10.1111/add.12998

37. Stead L.F., Buitrago D., Preciado N., Sanchez G., Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2013; (5): CD000165, doi: 10.1002/14651858.CD000165.pub4

38. Hartmann-Boyce J., Lancaster T., Stead L.F. Print-based self-help interventions for smoking cessation. Cochrane Database Syst Rev 2014; (6): CD001118, doi: 10.1002/14651858.CD001118.pub3

39. Stead L.F., Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2005; (2): CD001007, doi: 10.1002/14651858.CD001007.pub2.

40. Stead L.F., Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev 2012; 12: CD009670, doi: 10.1002/14651858.CD009670.pub2

41. Platonov D.Yu., Bel'diev S.N., Egorova I.V., Lazdin O.A., Berezina E.I., Andreeva E.V. et al. Pervye rossijskie klinicheskie rekomendacii po vedeniju bol'nyh s komorbidnoj patologiej: ocenivaem uroven' dokazatel'nosti [First Russian clinical recommendations for the management of patients with comorbid pathology: evaluate the evidence level]. Verhnevolzhskij medicinskij zhurnal [Upper Volga Medical Journal] 2018; 17(3): 23-32. (In Russ.)

42. Bel'diev S.N., Egorova I.V., Platonov D.Yu. Rekomendacii po primeneniju peroral'nyh antikoaguljantov u pacientov pozhilogo vozrasta: kriterii Birsa i dokazatel'naja medicina [Recommendations on the use of oral anticoagulants in elderly patients: Beers criteria and evidence-based medicine]. Medicina [Medicine] 2019; 7(4): 1-11, doi: 10.29234/2308-9113-2019-7-4-1-11. (In Russ.).